11-14281736-T-A

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BA1BP4BP7

This summary comes from the ClinGen Evidence Repository: The c.409-16A>T variant in RRAS2 is an intronic variant which is located in intron 4. It is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by UCSC Genome Browser (BP4, BP7). The highest population filtering allele frequency in gnomAD v2.1.1 is 0.6134 (97382/231122 alleles) in the Latino/Admixed American population, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as benign for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: BA1, BP4, BP7. (RASopathy VCEP specifications version 1.1; 9/17/2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA5894276/MONDO:0021060/127

Frequency

Genomes: 𝑓 0.37 ( 11566 hom., cov: 32)
Exomes 𝑓: 0.44 ( 139238 hom. )

Consequence

RRAS2
NM_012250.6 intron

Scores

2

Clinical Significance

Benign reviewed by expert panel B:5

Conservation

PhyloP100: -2.13

Publications

15 publications found
Variant links:
Genes affected
RRAS2 (HGNC:17271): (RAS related 2) This gene encodes a member of the R-Ras subfamily of Ras-like small GTPases. The encoded protein associates with the plasma membrane and may function as a signal transducer. This protein may play an important role in activating signal transduction pathways that control cell proliferation. Mutations in this gene are associated with the growth of certain tumors. Pseudogenes of this gene are found on chromosomes 1 and 2. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Apr 2010]
RRAS2 Gene-Disease associations (from GenCC):
  • Noonan syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • noonan syndrome 12
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics, Genomics England PanelApp
  • ovarian cancer
    Inheritance: Unknown Classification: NO_KNOWN Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

BP4
For more information check the summary or visit ClinGen Evidence Repository.
BP7
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
RRAS2NM_012250.6 linkc.409-16A>T intron_variant Intron 4 of 5 ENST00000256196.9 NP_036382.2 P62070-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
RRAS2ENST00000256196.9 linkc.409-16A>T intron_variant Intron 4 of 5 1 NM_012250.6 ENSP00000256196.4 P62070-1

Frequencies

GnomAD3 genomes
AF:
0.370
AC:
56281
AN:
151978
Hom.:
11569
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.199
Gnomad AMI
AF:
0.546
Gnomad AMR
AF:
0.507
Gnomad ASJ
AF:
0.428
Gnomad EAS
AF:
0.320
Gnomad SAS
AF:
0.408
Gnomad FIN
AF:
0.310
Gnomad MID
AF:
0.415
Gnomad NFE
AF:
0.448
Gnomad OTH
AF:
0.408
GnomAD2 exomes
AF:
0.421
AC:
97382
AN:
231122
AF XY:
0.421
show subpopulations
Gnomad AFR exome
AF:
0.187
Gnomad AMR exome
AF:
0.621
Gnomad ASJ exome
AF:
0.430
Gnomad EAS exome
AF:
0.313
Gnomad FIN exome
AF:
0.308
Gnomad NFE exome
AF:
0.439
Gnomad OTH exome
AF:
0.430
GnomAD4 exome
AF:
0.439
AC:
619829
AN:
1410756
Hom.:
139238
Cov.:
23
AF XY:
0.438
AC XY:
308190
AN XY:
703020
show subpopulations
African (AFR)
AF:
0.185
AC:
5852
AN:
31702
American (AMR)
AF:
0.600
AC:
23937
AN:
39914
Ashkenazi Jewish (ASJ)
AF:
0.423
AC:
10833
AN:
25590
East Asian (EAS)
AF:
0.314
AC:
11954
AN:
38082
South Asian (SAS)
AF:
0.419
AC:
33668
AN:
80380
European-Finnish (FIN)
AF:
0.321
AC:
17068
AN:
53176
Middle Eastern (MID)
AF:
0.431
AC:
2448
AN:
5680
European-Non Finnish (NFE)
AF:
0.454
AC:
488836
AN:
1077582
Other (OTH)
AF:
0.430
AC:
25233
AN:
58650
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
16589
33177
49766
66354
82943
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
14600
29200
43800
58400
73000
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.370
AC:
56288
AN:
152096
Hom.:
11566
Cov.:
32
AF XY:
0.364
AC XY:
27082
AN XY:
74344
show subpopulations
African (AFR)
AF:
0.198
AC:
8233
AN:
41494
American (AMR)
AF:
0.507
AC:
7749
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.428
AC:
1484
AN:
3466
East Asian (EAS)
AF:
0.319
AC:
1652
AN:
5174
South Asian (SAS)
AF:
0.408
AC:
1965
AN:
4820
European-Finnish (FIN)
AF:
0.310
AC:
3280
AN:
10570
Middle Eastern (MID)
AF:
0.418
AC:
123
AN:
294
European-Non Finnish (NFE)
AF:
0.448
AC:
30444
AN:
67980
Other (OTH)
AF:
0.408
AC:
861
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1736
3473
5209
6946
8682
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
548
1096
1644
2192
2740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.326
Hom.:
1448
Bravo
AF:
0.378
Asia WGS
AF:
0.398
AC:
1381
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

May 14, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Noonan syndrome 12 Benign:1
Nov 07, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

RASopathy Benign:1
Sep 17, 2024
ClinGen RASopathy Variant Curation Expert Panel
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The c.409-16A>T variant in RRAS2 is an intronic variant which is located in intron 4. It is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by UCSC Genome Browser (BP4, BP7). The highest population filtering allele frequency in gnomAD v2.1.1 is 0.6134 (97382/231122 alleles) in the Latino/Admixed American population, which is higher than the ClinGen RASopathy VCEP threshold (>0.0005) for BA1, and therefore meets this criterion (BA1). In summary, this variant meets the criteria to be classified as benign for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: BA1, BP4, BP7. (RASopathy VCEP specifications version 1.1; 9/17/2024) -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.78
CADD
Benign
3.7
DANN
Benign
0.74
PhyloP100
-2.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2303972; hg19: chr11-14303282; COSMIC: COSV56329562; API